PubMed Health⌕ Search

Biomedical subjects

M Uribe

Publications and source records attributed to M Uribe.

At least 109 records · Page 6Linked to original sources
PubMedDate not supplied

[Treatment of hepatorenal syndrome with dopamine and bromocriptine].

Two cirrhotic patients with hepatorenal syndrome were treated with Dopamine hydrochloride and Bromocriptine, a Dopamine agonist. Dopamine hydrochloride was given at a dosis of 0.30 to 0.90 mg/min. and Bromocriptine 15 mg/day. Although a transient raise of urinary output was observed in one patient, both patients died six to ten days later with an urinary output of less than 100 ml/day. Dopamine and Bromocriptine combined are of poor therapeutic value in hepatorenal syndrome.

Adult↗
PubMedDate not supplied

[Emphysematous cholecystitis (author's transl)].

A case of emphysematous cholecystitis is reported. The gallblader size in this case was 25 x 12 cms. The patient underwent successful cholecystectomy and responded adequately to cloramphenicol, peniciline and metronidazol. The late antibiotics are usually recommended due to the prevalence of Clostridia and Escherinchia bacterial infections in the gallbladder of patients with this illness.

Aged↗
PubMedDate not supplied

[Absorption and biological availability of drugs].

Bioavailability is a term used to indicate measurement of both, the relative amount of and administered drug that reaches the general circulation and the rate at which this occurs. Assessment of bioavailability indeally requires specific and sensitive methods for determination of drug concentrations in human body fluids. For the purposes of most bioavailability studies, it is sufficient to determine four indexes: maximum drug serum concentrations (Cmax), time of maximum drug concentration (tCmax) area under the drug serum half life of the drug. Potential drugs interactions and the effect of the disease state must also be evaluated, to adjust drug dosage in order to obtain an optimal therapeutic effect with minimal unwanted side effects.

Biological Availability↗
PubMedDate not supplied

[Hepatic changes caused by contraceptive steroids].

The number and type of contraceptive side effects is constantly increasing. Several abnormalities have been observed regarding liver function, these include: Jaundice, cholestasis, hepatitis, changes in the rate synthesis of many serum proteins and coagulation factors. One of the most dangerous complications in the liver is the risk to develop hepatic adenoma which has been reported in 250 cases. An even more dangerous complication is the development of liver cancer of several histological types which so far has been observed in 21 patients. Women receiving contraceptive steroids should be alert regarding their potential hazards and the physician must be informed of such risks and observe special control care in these patients.

Chemical and Drug Induced Liver Injury↗
PubMedDate not supplied

[Furosemide-amiloride combination in the treatment of ascitic-edema in patients with hepatic cirrhosis].

The combination of furosemide-amiloride was used in the management of fluid retention in 16 cirrhotic patients. The study lasted 60 days. In 15 out of the 16 patients a clinical response was observed, namely increased urinary volumen and reduction of abdominal girth. The body weight was reduced by a mean of 7.7 Kg. Serum potassium rose, within normal limits, in 14 patients and a reduction of urinary potassium elimination was observed. Mild hepatic encephalopathy was noticeable in 3 cases, rapidly responding to treatment reduction or withdrawal. The combination of furosemide-amiloride seems to be of value in the management of fluid retention in liver cirrhosis and is uncommonly associated to side effects.

Adult↗